Absci Corporation
NASDAQ:ABSIBiotechnology
Healthcare
$8.18 +1.04%
+$0.08 today
- Market cap
- $1.41B
- Beta
- 2.46
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$0.77
52W Low $2.24High $8.17
Volume 5.66M
Average 5.10M
Income Statement
Follow revenue through to earnings.
Revenue
$2.80M
FY 2025 · Annual
-38.2% YoYOperating Income
-$124.72M
FY 2025 · Annual
Net Income
-$115.18M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.78M | 5.75M | 5.72M | 4.53M | 2.8M |
| Cost of Revenue | 44.59M | 58.91M | 47.57M | 62.46M | 11.74M |
| Gross Profit | (39.8M) | (53.16M) | (41.85M) | (57.93M) | (8.94M) |
| Gross Margin | -832.4% | -925.0% | -731.9% | -1277.6% | -319.4% |
| Research & Development | 44.59M | 58.91M | 48.07M | 63.86M | 81.42M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 35.06M |
| Operating Expenses | 35.43M | 53.59M | 73.67M | 50.96M | 115.78M |
| Depreciation & Amortization | 6.65M | 13.04M | 14M | 13.39M | 11.74M |
| EBITDA | (67.68M) | (91.36M) | (79.68M) | (94.1M) | (103.16M) |
| EBITDA Margin | -1415.4% | -1589.6% | -1393.5% | -2075.4% | -3684.4% |
| Operating Income | (75.24M) | (106.75M) | (115.52M) | (108.89M) | (124.72M) |
| Operating Margin | -1573.4% | -1857.5% | -2020.2% | -2401.6% | -4454.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.43M | 972K | 1.01M | 565K | 209K |
| Other Income / Expenses | (34.62M) | 1.39M | 5.05M | 5.85M | 9.6M |
| Income Before Tax | (109.86M) | (105.37M) | (110.47M) | (103.04M) | (115.11M) |
| Pre-Tax Margin | -2297.3% | -1833.4% | -1931.9% | -2272.5% | -4111.2% |
| Income Tax Expense | (8.9M) | (461K) | 100K | 70K | 69K |
| Net Income | (100.96M) | (104.9M) | (110.57M) | (103.11M) | (115.18M) |
| Net Margin | -2111.3% | -1825.4% | -1933.6% | -2274.1% | -4113.7% |
| EPS (Basic) | (1.11) | (1.15) | (1.20) | (0.94) | (0.84) |
| EPS (Diluted) | (1.11) | (1.15) | (1.20) | (0.94) | (0.84) |
| 92.65M | 90.85M | 92.03M | 110.24M | 136.78M | |
| 92.65M | 90.85M | 92.03M | 110.24M | 136.78M |
ABSI Earnings Waterfall · TTM
NASDAQ:ABSI · Revenue to Net Income
Key Ratios
EPS$-0.83
Gross Margin-1188.5%
Net Margin-7766.0%
P/E Ratio-3.7
P/S Ratio1163.1
Analysis
$1.8M of revenue converted into -$118.4M of net income for the selected period. Gross margin is -1188.5% and net margin is -7766.0%, showing how much revenue survives after costs and taxes. EPS is $-0.83, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| S-3ASR | S-3ASR filing | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
How much revenue does ABSI generate?
Absci Corporation (ABSI) reported $2.80M of revenue in fiscal 2025.
Is ABSI profitable?
Absci Corporation (ABSI) reported -$115.18M of net income, with a net margin of -4113.7%.
Continue the stock analysis
Jump to another research area for this company.